Retatrutide 60mg Pen

Retatrutide research peptide

(LY3437943) is a synthetic triple receptor agonist that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR) — making it the most advanced incretin co-agonist to reach Phase 3 research stages. Unlike Semaglutide peptide which engages only GLP-1R, or Tirzepatide peptide which engages GLP-1R and GIPR, Retatrutide adds full glucagon receptor agonism — activating all three axes of the incretin and glucagon signalling system in a single research compound. PeptideCores supplies Retatrutide as independently HPLC verified research grade material at 99%+ purity with a batch-specific Certificate of Analysis from an independent third-party laboratory included on every order dispatched across Europe.

 

Retatrutide — Molecular Profile

Retatrutide is a 36 amino acid acylated peptide with a molecular weight of approximately 4759.4 g/mol and molecular formula C₂₁₀H₃₃₃N₅₇O₆₅S. The peptide incorporates a C20 fatty diacid chain attached via a gamma-glutamic acid linker, enabling albumin binding in research models and producing an extended duration of receptor activation compared to non-acylated peptide analogues. This structural feature is shared with other long-acting incretin research peptides and is responsible for the extended pharmacokinetic profile observed in research settings.

 

Triple Receptor Mechanism of Action

The research value of Retatrutide lies in its simultaneous engagement of three pharmacologically distinct receptor systems. Each receptor contributes unique downstream signalling effects in research models and their co-activation by a single molecule produces an integrated metabolic signalling environment not achievable with mono or dual agonists.

 

GLP-1 Receptor Agonism — Retatrutide activates GLP-1R expressed in pancreatic beta cells, the hypothalamus, brainstem and gastrointestinal tract. GLP-1R activation drives glucose-dependent insulin secretion, glucagon suppression from alpha cells, delayed gastric emptying and central appetite suppression signalling — mechanisms extensively characterised in prior incretin receptor research.

 

GIP Receptor Agonism — Co-agonism at GIPR adds incretin pathway amplification, direct effects on adipose tissue lipid metabolism, emerging bone biology research applications and potentiation of insulin secretion beyond GLP-1R activation alone. The combined GLP-1R and GIPR signalling produces synergistic incretin effects studied in metabolic research programmes.

 

Glucagon Receptor Agonism — The addition of GCGR agonism is what fundamentally distinguishes Retatrutide from all previously studied incretin peptides. Glucagon receptor activation in research models drives hepatic glucose output regulation, thermogenic energy expenditure via brown adipose tissue activation, lipolysis in adipose tissue and hepatic fatty acid oxidation — collectively producing a broader metabolic signalling profile than any dual agonist can achieve.

 

Research Applications

Retatrutide research peptide is studied across several distinct research domains that reflect the broad expression pattern of its three target receptors. In metabolic biology research, its triple receptor engagement produces a complex signalling environment relevant to glucose homeostasis, insulin sensitivity, hepatic lipid metabolism, adipose tissue biology and energy expenditure regulation — areas where no prior mono or dual agonist has been able to engage all relevant receptor pathways simultaneously.

 

In comparative incretin research, Retatrutide is used alongside Semaglutide and Tirzepatide to study the incremental contribution of each additional receptor target to overall metabolic outcomes. By comparing experimental results across single, dual and triple agonist conditions, researchers can isolate the specific contribution of GIPR and GCGR activation to observed effects — a mechanistic dissection not possible with any single compound alone. In hepatic research, the glucagon receptor component drives significant liver-specific effects including regulation of hepatic glucose output and fatty acid oxidation — making Retatrutide particularly relevant for non-alcoholic fatty liver disease models and liver energy metabolism research programmes.

 

COA and Purity Verification

Every Retatrutide research pack supplied by PeptideCores is independently HPLC verified at 99%+ purity by a third-party laboratory with no commercial relationship to PeptideCores. Mass spectrometry molecular identity confirmation is included alongside HPLC chromatogram data in the batch-specific Certificate of Analysis provided with every order. Researchers requiring COA documentation prior to ordering can request the current batch certificate via the contact page before placing an order. For a full explanation of how to read a Certificate of Analysis see our COA guide.

 

Product Specifications

Specification Detail

Compound Retatrutide (LY3437943)

Quantity 60mg research pack

Purity 99%+ HPLC verified — independent third-party laboratory

Molecular Weight ~4759.4 g/mol

Molecular Formula C₂₁₀H₃₃₃N₅₇O₆₅S

Amino Acids 36 residues

Receptor Targets GLP-1R / GIPR / GCGR (triple agonist)

Form Lyophilised powder

COA Batch-specific, independent third-party laboratory

Storage −20°C lyophilised / 4°C once reconstituted

Shipping EU-wide, dispatched within 24 hours, full tracking provided

Research Use Laboratory research only — not for human or veterinary use

Sourcing Retatrutide Research Peptide in Europe

PeptideCores supplies Retatrutide research peptide to laboratories and research institutions across all European countries. Every 60mg research pack is dispatched within 24 hours of order confirmation in discreet packaging with no reference to contents on the outer packaging. Full order tracking is provided from dispatch through to delivery. Personal data for all European customers is handled in strict compliance with GDPR regulations. Researchers across the EU, UK, Netherlands, Germany, France, Spain and all other European destinations can order with confidence from PeptideCores as a verified European research peptide supplier.

 

Retatrutide supplied by PeptideCores is intended for laboratory research purposes only. It is not intended for human or veterinary use, diagnosis, treatment or prevention of any condition or disease. Only qualified researchers should handle this compound in appropriate laboratory settings following all relevant safety guidelines and applicable regulations. PeptideCores makes no therapeutic claims regarding this compound.